Biophytis and LynxKite use Nebius AI Cloud for their joint AI-driven longevity drug-discovery work. Biophytis’s March 2026 announcement describes computational research and a GTC demonstration of the MAS receptor and its lead drug candidate BIO101. The demonstration at the Nebius booth showed biological target modeling using advanced computational tools and large-scale GPU computing.
LynxKite described the joint GTC presentation with Biophytis, Nebius and Accenture as combining biological insight, graph-based AI workflows and scalable GPU infrastructure. BIO101 and the MAS receptor target served as the reference case. LynxKite reported that early-stage discovery timelines were moving from approximately 24 months to 6–8 months.
A separate project announcement covers receptor modeling and AI-guided molecule design using NVIDIA tools and neoclouds including Nebius.
LynxKite at NVIDIA GTC 2026: AI-Driven Drug Discovery
13 Oct 2026 · lynxkite.com · Web page
LynxKite joined Biophytis, Nebius and Accenture at GTC to demonstrate AI-driven drug discovery combining biological insight, graph-based AI workflows and scalable GPU infrastructure. Biophytis’s BIO101 and MAS receptor target supplied the reference case. LynxKite reported early-stage discovery timelines moving from approximately 24 months to 6–8 months.
LynxKite at NVIDIA GTC 2026: AI-Driven Drug Discovery13 Oct 2026 · lynxkite.com · Web pageLynxKite joined Biophytis, Nebius and Accenture at GTC to demonstrate AI-driven drug discovery combining biological insight, graph-based AI workflows and scalable GPU infrastructure. Biophytis’s BIO101 and MAS receptor target supplied the reference case. LynxKite reported early-stage discovery timelines moving from approximately 24 months to 6–8 months.
Longevity discovery on Nebius AI Cloud
26 Mar 2026 · Biophytis · Web page
Biophytis and LynxKite are developing AI-driven longevity drug-discovery approaches powered by Nebius AI Cloud. Their GTC demonstration at the Nebius booth featured biological target modeling using the MAS receptor and BIO101.
Longevity discovery on Nebius AI Cloud26 Mar 2026 · Biophytis · Web pageBiophytis and LynxKite are developing AI-driven longevity drug-discovery approaches powered by Nebius AI Cloud. Their GTC demonstration at the Nebius booth featured biological target modeling using the MAS receptor and BIO101.
Computational longevity project
27 Sept 2026 · Biophytis · PDF
Describes MAS-receptor modeling, AI-guided molecule design and LynxKite scaling GPU computation with NVIDIA toolkits and neoclouds such as Nebius.
Computational longevity project27 Sept 2026 · Biophytis · PDFDescribes MAS-receptor modeling, AI-guided molecule design and LynxKite scaling GPU computation with NVIDIA toolkits and neoclouds such as Nebius.
#nvidiagtc #gtc26 | Nebius
16 Mar 2026 · www.linkedin.com · Web page
Nebius lists LynxKite and Biophytis for a joint demonstration at its GTC booth. It says the featured teams are running AI workloads on Nebius infrastructure and building and deploying on Nebius.
#nvidiagtc #gtc26 | Nebius16 Mar 2026 · www.linkedin.com · Web pageNebius lists LynxKite and Biophytis for a joint demonstration at its GTC booth. It says the featured teams are running AI workloads on Nebius infrastructure and building and deploying on Nebius.
At NVIDIA GTC 2026, LynxKite joined BIOPHYTIS - Live Healthier Longer, Nebius and Accenture to present a fully integrated AI-driven drug discovery approach—combining biological insight, graph-based… | LynxKite
24 Mar 2026 · www.linkedin.com · Web page
LynxKite presented an AI-driven drug-discovery approach with Biophytis, Nebius and Accenture at GTC, combining graph-based AI workflows and scalable GPU infrastructure. The demonstration used Biophytis’s BIO101 and MAS receptor target as its reference case. LynxKite reported early-stage discovery timelines moving from approximately 24 months to 6–8 months.
At NVIDIA GTC 2026, LynxKite joined BIOPHYTIS - Live Healthier Longer, Nebius and Accenture to present a fully integrated AI-driven drug discovery approach—combining biological insight, graph-based… | LynxKite24 Mar 2026 · www.linkedin.com · Web pageLynxKite presented an AI-driven drug-discovery approach with Biophytis, Nebius and Accenture at GTC, combining graph-based AI workflows and scalable GPU infrastructure. The demonstration used Biophytis’s BIO101 and MAS receptor target as its reference case. LynxKite reported early-stage discovery timelines moving from approximately 24 months to 6–8 months.
Biophytis is a Paris-based clinical-stage biotechnology company developing drug candidates for age-related muscular and metabolic diseases. Its lead candidate, BIO101 (20-hydroxyecdysone), is an oral small molecule being studied to improve muscle function and mobility. Its principal development programs are SARA for older adults with sarcopenia and OBA for patients with obesity. The company also operates a longevity research platform combining biological research and AI-assisted technologies to discover additional drug candidates.
Biophytis files obesity trial amendment to study weight regain
Biophytis submitted an amendment to Brazil’s ANVISA to expand its Phase 2 OBA study with follow-up after semaglutide discontinuation. The additional phase would assess weight regain and BIO101’s potential role in limiting it.
Biophytis reported €3 million in cash following warrant exercises and debt-to-equity conversions. It expected its Phase 2 obesity study to start in Q1 2027.
Drug discovery and treatments for age-related diseases · Health
How they use Nebius AI Cloud
Biophytis and LynxKite use Nebius AI Cloud for their joint AI-driven longevity drug-discovery work. Biophytis’s March 2026 announcement describes computational research and a GTC demonstration of the MAS receptor and its lead drug candidate BIO101. The demonstration at the Nebius booth showed biological target modeling using advanced computational tools and large-scale GPU computing.
LynxKite described the joint GTC presentation with Biophytis, Nebius and Accenture as combining biological insight, graph-based AI workflows and scalable GPU infrastructure. BIO101 and the MAS receptor target served as the reference case. LynxKite reported that early-stage discovery timelines were moving from approximately 24 months to 6–8 months.
A separate project announcement covers receptor modeling and AI-guided molecule design using NVIDIA tools and neoclouds including Nebius.
LynxKite at NVIDIA GTC 2026: AI-Driven Drug Discovery
13 Oct 2026 · lynxkite.com · Web page
LynxKite joined Biophytis, Nebius and Accenture at GTC to demonstrate AI-driven drug discovery combining biological insight, graph-based AI workflows and scalable GPU infrastructure. Biophytis’s BIO101 and MAS receptor target supplied the reference case. LynxKite reported early-stage discovery timelines moving from approximately 24 months to 6–8 months.
LynxKite at NVIDIA GTC 2026: AI-Driven Drug Discovery13 Oct 2026 · lynxkite.com · Web pageLynxKite joined Biophytis, Nebius and Accenture at GTC to demonstrate AI-driven drug discovery combining biological insight, graph-based AI workflows and scalable GPU infrastructure. Biophytis’s BIO101 and MAS receptor target supplied the reference case. LynxKite reported early-stage discovery timelines moving from approximately 24 months to 6–8 months.
Longevity discovery on Nebius AI Cloud
26 Mar 2026 · Biophytis · Web page
Biophytis and LynxKite are developing AI-driven longevity drug-discovery approaches powered by Nebius AI Cloud. Their GTC demonstration at the Nebius booth featured biological target modeling using the MAS receptor and BIO101.
Longevity discovery on Nebius AI Cloud26 Mar 2026 · Biophytis · Web pageBiophytis and LynxKite are developing AI-driven longevity drug-discovery approaches powered by Nebius AI Cloud. Their GTC demonstration at the Nebius booth featured biological target modeling using the MAS receptor and BIO101.
Computational longevity project
27 Sept 2026 · Biophytis · PDF
Describes MAS-receptor modeling, AI-guided molecule design and LynxKite scaling GPU computation with NVIDIA toolkits and neoclouds such as Nebius.
Computational longevity project27 Sept 2026 · Biophytis · PDFDescribes MAS-receptor modeling, AI-guided molecule design and LynxKite scaling GPU computation with NVIDIA toolkits and neoclouds such as Nebius.
#nvidiagtc #gtc26 | Nebius
16 Mar 2026 · www.linkedin.com · Web page
Nebius lists LynxKite and Biophytis for a joint demonstration at its GTC booth. It says the featured teams are running AI workloads on Nebius infrastructure and building and deploying on Nebius.
#nvidiagtc #gtc26 | Nebius16 Mar 2026 · www.linkedin.com · Web pageNebius lists LynxKite and Biophytis for a joint demonstration at its GTC booth. It says the featured teams are running AI workloads on Nebius infrastructure and building and deploying on Nebius.
At NVIDIA GTC 2026, LynxKite joined BIOPHYTIS - Live Healthier Longer, Nebius and Accenture to present a fully integrated AI-driven drug discovery approach—combining biological insight, graph-based… | LynxKite
24 Mar 2026 · www.linkedin.com · Web page
LynxKite presented an AI-driven drug-discovery approach with Biophytis, Nebius and Accenture at GTC, combining graph-based AI workflows and scalable GPU infrastructure. The demonstration used Biophytis’s BIO101 and MAS receptor target as its reference case. LynxKite reported early-stage discovery timelines moving from approximately 24 months to 6–8 months.
At NVIDIA GTC 2026, LynxKite joined BIOPHYTIS - Live Healthier Longer, Nebius and Accenture to present a fully integrated AI-driven drug discovery approach—combining biological insight, graph-based… | LynxKite24 Mar 2026 · www.linkedin.com · Web pageLynxKite presented an AI-driven drug-discovery approach with Biophytis, Nebius and Accenture at GTC, combining graph-based AI workflows and scalable GPU infrastructure. The demonstration used Biophytis’s BIO101 and MAS receptor target as its reference case. LynxKite reported early-stage discovery timelines moving from approximately 24 months to 6–8 months.
Biophytis is a Paris-based clinical-stage biotechnology company developing drug candidates for age-related muscular and metabolic diseases. Its lead candidate, BIO101 (20-hydroxyecdysone), is an oral small molecule being studied to improve muscle function and mobility. Its principal development programs are SARA for older adults with sarcopenia and OBA for patients with obesity. The company also operates a longevity research platform combining biological research and AI-assisted technologies to discover additional drug candidates.
Biophytis files obesity trial amendment to study weight regain
Biophytis submitted an amendment to Brazil’s ANVISA to expand its Phase 2 OBA study with follow-up after semaglutide discontinuation. The additional phase would assess weight regain and BIO101’s potential role in limiting it.
Biophytis reported €3 million in cash following warrant exercises and debt-to-equity conversions. It expected its Phase 2 obesity study to start in Q1 2027.
